Jan Endell - Concepedia

Author

Jan Endell

MorphoSys (Germany)ORCID

Also Known As

Endell, Jan, J Endell, J. Endell, Jan Endell

Publications

867

Citations

H-Index

Concepts

All Affiliations

MorphoSys (Germany)Technical University of Munich Ludwig-Maximilians-Universität München Heidelberg University University of Cologne

About

Jan Endell is an author at MorphoSys (Germany) specializing in medicine, immunotherapy, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	160
2	Health Sciences	3	3	54
3	Allergy	2	2	28
4	Engineering	1	1	10
5	Biomedical Engineering	1	1	10

Jan Endell

Publications

795

Citations

H-Index

Page 1

	Year	Citations
Green Fluorescent Protein-Tagged Adeno-Associated Virus Particles Allow the Study of Cytosolic and Nuclear Trafficking Kerstin Lux, Nico Goerlitz, Stefanie Schlemminger, Journal of Virology	2005	146
Combinatorial engineering of a gene therapy vector: directed evolution of adeno‐associated virus Luca Perabò, Jan Endell, Susan King, The Journal of Gene Medicine	2005	132
Heparan Sulfate Proteoglycan Binding Properties of Adeno-Associated Virus Retargeting Mutants and Consequences for Their In Vivo Tropism Luca Perabò, Daniela Goldnau, Kathryn White, Journal of Virology	2006	128
Therapeutic Antibodies to Human L1CAM: Functional Characterization and Application in a Mouse Model for Ovarian Carcinoma Silke Wolterink, Gerhard Moldenhauer, Mina Fogel, Cancer Research Immunocytochemical TechniqueImmunologyImmunotherapyCancer BiologyTumor Biology	2010	68
Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies Pedro Horna, Grzegorz S. Nowakowski, Jan Endell, Blood	2019	52
α-Radioimmunotherapy with 213Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma Katharina Teiluf, Christof Seidl, Birgit Blechert, Oncotarget	2014	47
A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma Marc S. Raab, Manik Chatterjee, Hartmut Goldschmidt, Blood	2016	38
The Activity of MOR202, a Fully Human Anti-CD38 Antibody, Is Complemented by ADCP and Is Synergistically Enhanced by Lenalidomide in Vitro and in Vivo Jan Endell, Rainer Boxhammer, Cornelia Wurzenberger, Blood	2012	35
Effect of IMiD compounds on CD38 expression on multiple myeloma cells: MOR202, a human CD38 antibody in combination with pomalidomide. Rainer Boxhammer, Stefan Steidl, Jan Endell Journal of Clinical Oncology Hematological MalignancyHuman Cd38 AntibodyMedicineMalignant Blood DisorderImmunology	2015	26
MOR202, a Human Anti-CD38 Monoclonal Antibody, Mediates Potent Tumoricidal Activity In Vivo and Shows Synergistic Efficacy in Combination with Different Antineoplastic Compounds Rainer Boxhammer, Johannes Weirather, Stefan Steidl, Blood	2015	22

Page 1